AR075097A1 - Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia - Google Patents

Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia

Info

Publication number
AR075097A1
AR075097A1 ARP090104261A ARP090104261A AR075097A1 AR 075097 A1 AR075097 A1 AR 075097A1 AR P090104261 A ARP090104261 A AR P090104261A AR P090104261 A ARP090104261 A AR P090104261A AR 075097 A1 AR075097 A1 AR 075097A1
Authority
AR
Argentina
Prior art keywords
polymal
sulfonil
penyl
quinazolin
thiophen
Prior art date
Application number
ARP090104261A
Other languages
English (en)
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075097(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of AR075097A1 publication Critical patent/AR075097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formas polimorficas cristalinas D, A, C, que corresponden a sales de potasio, sodio, calcio y trometamina. Reivindicacion 1: Una sal que comprende un compuesto de la formula (1) y un ion seleccionado del grupo que consiste en sodio, potasio, calcio, L-lisina, amonio, magnesio, L-arginina, trometamina, N-etilglucamina y N-metilglucamina.
ARP090104261A 2008-11-05 2009-11-04 Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia AR075097A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/265,699 US20090156620A1 (en) 2007-05-02 2008-11-05 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Publications (1)

Publication Number Publication Date
AR075097A1 true AR075097A1 (es) 2011-03-09

Family

ID=41460405

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104261A AR075097A1 (es) 2008-11-05 2009-11-04 Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia

Country Status (14)

Country Link
US (2) US20090156620A1 (es)
EP (1) EP2358706A1 (es)
JP (1) JP2012508243A (es)
KR (1) KR20110093843A (es)
CN (1) CN102272130A (es)
AR (1) AR075097A1 (es)
AU (1) AU2009313565A1 (es)
BR (1) BRPI0921649A2 (es)
CA (1) CA2742601A1 (es)
CL (1) CL2009002040A1 (es)
MX (1) MX2011004841A (es)
RU (1) RU2011122385A (es)
TW (1) TW201022252A (es)
WO (1) WO2010054020A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058284B2 (en) * 2005-11-03 2011-11-15 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
CN103339126B (zh) * 2010-12-03 2016-06-29 博尔托拉制药公司 式(i)化合物的固态形式及其药物组合物、剂型和使用方法
CN103288761B (zh) * 2012-02-25 2017-08-11 浙江华海药业股份有限公司 一种合成1，2，3，4‑喹唑啉‑2，4‑二酮衍生物的新方法
WO2018096517A1 (en) * 2016-11-28 2018-05-31 Parayil Sarin Novel organic crystalline salt of haloacetic acid
CN115490643A (zh) * 2022-11-21 2022-12-20 南京合创药业有限公司 一种一锅法合成3-二氯苯基-6-氟-2,4(1h,3h)-喹唑啉二酮的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
US8058284B2 (en) * 2005-11-03 2011-11-15 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
AU2008247483A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible P2Y12 inhibitor
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Also Published As

Publication number Publication date
CN102272130A (zh) 2011-12-07
CL2009002040A1 (es) 2010-09-10
RU2011122385A (ru) 2012-12-20
EP2358706A1 (en) 2011-08-24
TW201022252A (en) 2010-06-16
JP2012508243A (ja) 2012-04-05
CA2742601A1 (en) 2010-05-14
WO2010054020A1 (en) 2010-05-14
KR20110093843A (ko) 2011-08-18
US20120129876A1 (en) 2012-05-24
BRPI0921649A2 (pt) 2016-02-10
US20090156620A1 (en) 2009-06-18
MX2011004841A (es) 2011-07-28
AU2009313565A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
AR075097A1 (es) Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
AR121611A2 (es) Inhibidores de glucosilceramida sintasa
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
GT200600420A (es) Sales novedosas de lisina de derivados de acido 4-((fenoxialquil)tio)-fenoxiacetico
AR067775A1 (es) (2s,3r)-n-(2-((3- piridinil) metil)-1- azabiciclo (2.2.2= oct-3-il) benzofuran -2- carboxamida, formas de sales y metodos de uso
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
ECSP12012026A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EA201100969A1 (ru) Солевые формы органического соединения
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
CO6241155A2 (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
BR112014009190A8 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
EA200900732A1 (ru) Кристаллическая калиевая соль аналогов липоксина а
UY37987A (es) Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3- metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico.
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
AR077692A1 (es) Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
EA201791321A1 (ru) Составы ингибитора lfa-1
UY34647A (es) Composiciones farmacéuticas
AR058053A1 (es) Formas cristalinas polimorficas de la sal de di- sodio del acido n- (5 -clorosaliciloil)-8- aminocaprilico
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"

Legal Events

Date Code Title Description
FB Suspension of granting procedure